Information for Participants
The MAMA Study is designed to find out whether it is better for women who have inflammatory arthritis and are pregnant to temporarily stop or to continue taking biologic medications.
Currently both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK; this varies between different hospitals around the UK. The MAMA Study is looking to provide an answer on which is the better approach.
How will we do this?
Women who take part in the MAMA Study will be allocated at random to one of the following groups:
The continuing group. Women in this group will continue taking their biologic thoughout pregnancy.
OR
The stopping group. Women in this group will stop their biologics before the third trimester (28 weeks) of pregnancy, and restart no earlier than 2 weeks post-pregnancy.
Other than stopping or continuing your current biologic by 28 weeks' gestation, no other changes will be made to your arthritis treatment as a result of being in this study.
Both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK.
Who can take part in MAMA?
Pregnant women less than 28 completed weeks of gestation prescribed a biologic for Autoimmune Inflammatory Arthritis and meet the eligibility criteria for the MAMA trial.
How can I take part in MAMA?
If you would like more information or are interested in taking part in the MAMA Study, please get in touch with the team at the MAMA Co-ordinating Centre.
Latest update
